BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Citation
Sevindik, Ö. G., Chen, C., Yang, J., Farooqui, M. Z. H. ve Paszkiewicz-Kozik, E. (2023). BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.Abstract
...
WoS Q Kategorisi
Q1Source
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)Volume
41Issue
16Collections
- Bildiri Koleksiyonu [515]
- WoS İndeksli Yayınlar Koleksiyonu [6461]